A Phase 1 interventional study of VRC07-523LS and Placebo in HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-05.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) — 10 open to participants now, 15 under way, 1 of them phase 3. HIV Infections · National Institute of Allergy and Infectious Diseases (NIAID).
Among the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 266th largest by enrollment of the 883 interventional ones that give a count, is one of 11 that started in 2018, is one of 365 in phase 1, and was the 983rd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →10 of the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 12 countries. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Peru
Ages 18–60 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Brazil, Peru
Ages 18–70
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,034 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 411 · Phase 2 276 · Phase 3 101 · Phase 4 10
First in 1984; this study’s year is marked. 11 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 59 across the 883 interventional studies, 174 across the 136 observational. Of the 962 that completed or were terminated, 130 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,448 studies on the registry; 181 are open to participants now.
Of its 407 completed or terminated interventional studies of FDA-regulated products, 302 (74%) have results posted.
5 of the studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06796686National Institute of Allergy and Infectious Diseases (NIAID)Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health | 2027-01-15 |
| NCT06557785National Institute of Allergy and Infectious Diseases (NIAID)A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV | 2027-03-09 |
| NCT07342491National Institute of Allergy and Infectious Diseases (NIAID)Dasatinib for HIV-1 Reservoir Reduction | 2027-04-09 |
| NCT06508749National Institute of Allergy and Infectious Diseases (NIAID)The Tatelo Plus Study | 2027-09-03 |
| NCT06665646National Institute of Allergy and Infectious Diseases (NIAID)Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706 | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected adults.
This study will evaluate the safety, tolerability, and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected adults.
Participants will be randomly assigned to one of six groups. Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by intravenous (IV) infusion at Weeks 0, 16, 32, 48, and 64. Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64. Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64. Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by subcutaneous (SC) injection at Weeks 0, 16, 32, 48, and 64. Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64. Participants in Group 6 will receive 2.5 mg/kg of VRC07-523LS or placebo by intramuscular (IM) injection at Weeks 0, 16, 32, 48, and 64.
Participants will attend numerous study visits throughout the course of the study, beginning at Week 0 through Week 112. Visits may include physical examinations, blood and urine collection, HIV testing, risk reduction counseling, and questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General and Demographic Criteria
-Related Criteria:
Laboratory Inclusion Values
Hemogram/Complete Blood Count (CBC)
Chemistry
Virology
Urine
Reproductive Status
Reproductive status: A volunteer who was assigned female sex at birth must:
Exclusion Criteria:
General
Vaccines and other Injections
Immune System
medical conditions
Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
Asthma other than mild or moderate, well-controlled asthma. (Symptoms of asthma severity as defined in the most recent National Asthma Education and Prevention Program (NAEPP) Expert Panel report). Exclude a volunteer who:
Hypertension:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
Biological: VRC07-523LS
Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
Biological: VRC07-523LS
Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
Biological: VRC07-523LS
Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
Biological: VRC07-523LS
Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
Biological: VRC07-523LS
Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
Biological: VRC07-523LS
Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
Biological: Placebo
Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
Also known as: VRC-HIVMAB075-00-AB
Sodium Chloride for Injection USP, 0.9%; administered by IM injection
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented
Time frame: Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented
Time frame: Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64
Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Symptoms is the maximum of the individual systemic reactogenicities excluding body temperature for a participant.
Time frame: Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64
Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT)
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Chemistry and Hematology Laboratory Measures - Creatinine
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Chemistry and Hematology Laboratory Measures - Hemoglobin
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC)
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC).
The number (percentage) of participants with lab grade \>= 1 for alanine aminotransferase (ALT), creatinine, hemoglobin, lymphocyte count, neutrophil count, platelets, white blood cells (WBC) was summarized by arm
Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
VRC07523LS Serum Concentrations
VRC07523LS serum concentrations measured in healthy human subjects after up to five administrations of the study product via the IV, SC or IM routes at various doses. Serum concentrations between the first and second study product administrations (Target Visit Day 0-112) were measured using ELISA assay in all enrolled participants. Serum concentrations after the second study product administrations (Target Visit Day 168-784) were measured using BAMA (LUMINEX) assay in a subset of participants enrolled in each treatment group and all particiants in plocebo group. serum concentrations below the lower limit of quantification (LLoQ) were replaced by half the LLoQ. Thus, concentrations below the LLoQ when measured by the ELISA assay were replaced by 0.5 ug/ml and concentrations below the LLoQ when measured by the BAMA assay were replaced by 0.02285 ug/ml.
Time frame: Target Visit Days 0, 3, 6, 28, 56, 84, 112, 168, 224, 280, 336, 392, 448, 504, 560, 616, 672, 728, 784 (i.e., visit numbers 2 through 20)
Occurrence of Antidrug Antibodies (ADA)
Antidrug antibodies (ADA) are most typically detected and characterized using a tiered testing strategy. In Tier I, a sensitive binding assay is used to determine if samples may have ADA present. In Tier II, the response is confirmed, typically by establishing the specificity of the response by competition with free drug. In Tier III, the response is characterized, typically with a neutralization reduction assay and/or a titering assay.
Time frame: Day 0, 6, 112, 224, 448
Magnitude and Breadth of Neutralizing Antibody Responses Against Autologous Viral Isolates as Assessed by Area Under the Magnitude-breadth Curves 8, 72, 88 Weeks After the First Study Product Administration.
Magnitude-breadth characterize the magnitude (ID50 or ID80 titers) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the fraction of assays with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) is calculated as the average of the log10-based ID50 or ID80 titers over the panel of isolates. Isolates includes: H703_0646_051sN, H703_1471_190s, H703_1750_140Es, H704_0726_080sN, H704_1535_030sN, H704_2544_140eN01, PVO.4.
Time frame: Weeks 8, 72, and 88 following the first study product administration
| Milestone | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| Started | 19 | 19 | 21 | 21 | 20 | 21 | 3 |
| Safety population | 19 | 19 | 21 | 21 | 20 | 21 | 3 |
| Completed | 13 | 16 | 16 | 14 | 14 | 14 | 3 |
| Not completed | 6 | 3 | 5 | 7 | 6 | 7 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 3 | 4 | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 2 | 3 | 3 | 3 | 0 |
| Withdrew: Participant unable to adhere to visit | 0 | 1 | 0 | 0 | 2 | 2 | 0 |
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented
| Participants | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| None | 12 | 11 | 15 | 8 | 5 | 7 | 2 |
| Mild | 6 | 8 | 5 | 11 | 15 | 13 | 1 |
| Moderate | 1 | 0 | 1 | 2 | 0 | 1 | 0 |
| Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented
| Participants | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| Erythema/Redness — None | 14 | 15 | 16 | 7 | 7 | 19 | 3 |
| Erythema/Redness — Not gradable | 3 | 4 | 3 | 2 | 3 | 0 | 0 |
| Erythema/Redness — Gr 1: 2.5 - less than 5cm dim. | 0 | 0 | 1 | 2 | 2 | 0 | 0 |
| Erythema/Redness — Gr 1: 6.25 - less than 25cm^2 area | 1 | 0 | 0 | 4 | 3 | 2 | 0 |
| Erythema/Redness — Gr 2: 5 - less than 10cm dim. | 0 | 0 | 1 | 2 | 5 | 0 | 0 |
| Erythema/Redness — Gr 2: 25 - less than 100cm^2 area | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Erythema/Redness — Gr 3: >= 10cm dim. | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Erythema/Redness — Gr 3: >= 100cm^2 area | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Erythema/Redness — Gr 3: complications AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythema/Redness — Gr 4: complications AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythema/Redness — Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Induration/Swelling — None | 19 | 16 | 20 | 12 | 12 | 18 | 3 |
| Induration/Swelling — Not gradable | 0 | 3 | 1 | 2 | 6 | 2 | 0 |
| Induration/Swelling — Gr 1: 2.5 - less than 5cm dim. | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Induration/Swelling — Gr 1: 6.25 - less than 25cm^2 area | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Induration/Swelling — Gr 2: 5 - less than 10cm dim. | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Induration/Swelling — Gr 2: 25 - less than 100cm^2 area | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Induration/Swelling — Gr 3: >= 10cm dim. | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Induration/Swelling — Gr 3: >= 100cm^2 area | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Induration/Swelling — Gr 3: complications AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Induration/Swelling — Gr 4: complications AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Induration/Swelling — Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythema and/or Induration — None | 14 | 15 | 16 | 6 | 6 | 17 | 3 |
| Erythema and/or Induration — Not gradable | 3 | 4 | 3 | 2 | 4 | 2 | 0 |
| Erythema and/or Induration — Gr 1: 2.5 - less than 5cm dim. | 0 | 0 | 1 | 3 | 2 | 0 | 0 |
| Erythema and/or Induration — Gr 1: 6.25 - less than 25cm^2 area | 1 | 0 | 0 | 4 | 3 | 2 | 0 |
| Erythema and/or Induration — Gr 2: 5 - less than 10cm dim. | 0 | 0 | 1 | 2 | 4 | 0 | 0 |
| Erythema and/or Induration — Gr 2: 25 - less than 100cm^2 area | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Erythema and/or Induration — Gr 3: >= 10cm dim. | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Erythema and/or Induration — Gr 3: >= 100cm^2 area | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Erythema and/or Induration — Gr 3: complications AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythema and/or Induration — Gr 4: complications AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythema and/or Induration — Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Symptoms is the maximum of the individual systemic reactogenicities excluding body temperature for a participant.
| Participants | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| Malaise and/or fatigue — None | 10 | 10 | 7 | 12 | 13 | 14 | 1 |
| Malaise and/or fatigue — Mild | 6 | 5 | 7 | 6 | 6 | 4 | 2 |
| Malaise and/or fatigue — Moderate | 3 | 4 | 5 | 3 | 1 | 3 | 0 |
| Malaise and/or fatigue — Severe | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Malaise and/or fatigue — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Myalgia — None | 18 | 16 | 14 | 18 | 17 | 17 | 3 |
| Myalgia — Mild | 1 | 3 | 2 | 2 | 3 | 4 | 0 |
| Myalgia — Moderate | 0 | 0 | 4 | 1 | 0 | 0 | 0 |
| Myalgia — Severe | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Myalgia — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Headache — None | 13 | 11 | 4 | 12 | 16 | 13 | 2 |
| Headache — Mild | 4 | 6 | 12 | 6 | 4 | 7 | 1 |
| Headache — Moderate | 2 | 2 | 5 | 3 | 0 | 1 | 0 |
| Headache — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Headache — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nausea — None | 15 | 15 | 17 | 16 | 18 | 18 | 2 |
| Nausea — Mild | 4 | 2 | 1 | 5 | 1 | 3 | 1 |
| Nausea — Moderate | 0 | 2 | 3 | 0 | 1 | 0 | 0 |
| Nausea — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nausea — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chills — None | 19 | 17 | 13 | 20 | 18 | 20 | 2 |
| Chills — Mild | 0 | 1 | 5 | 1 | 2 | 1 | 1 |
| Chills — Moderate | 0 | 1 | 3 | 0 | 0 | 0 | 0 |
| Chills — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chills — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arthralgia — None | 19 | 16 | 14 | 19 | 19 | 19 | 3 |
| Arthralgia — Mild | 0 | 3 | 4 | 1 | 1 | 2 | 0 |
| Arthralgia — Moderate | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Arthralgia — Severe | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Arthralgia — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Facial flushing — None | 19 | 18 | 17 | 19 | 19 | 19 | 3 |
| Facial flushing — Mild | 0 | 1 | 4 | 2 | 1 | 2 | 0 |
| Facial flushing — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Facial flushing — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Facial flushing — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-exertional dyspnea — None | 19 | 18 | 19 | 21 | 19 | 21 | 3 |
| Non-exertional dyspnea — Mild | 0 | 1 | 2 | 0 | 1 | 0 | 0 |
| Non-exertional dyspnea — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-exertional dyspnea — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-exertional dyspnea — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-exertional tachycardia — None | 19 | 19 | 21 | 21 | 20 | 21 | 3 |
| Non-exertional tachycardia — Mild | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-exertional tachycardia — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-exertional tachycardia — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-exertional tachycardia — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unexplained diaphoresis — None | 19 | 19 | 19 | 20 | 19 | 21 | 3 |
| Unexplained diaphoresis — Mild | 0 | 0 | 2 | 1 | 1 | 0 | 0 |
| Unexplained diaphoresis — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unexplained diaphoresis — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unexplained diaphoresis — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Generalized Pruritus — None | 19 | 19 | 21 | 21 | 19 | 21 | 3 |
| Generalized Pruritus — Mild | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Generalized Pruritus — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Generalized Pruritus — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Generalized Pruritus — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urticaria — None | 19 | 19 | 21 | 21 | 20 | 21 | 3 |
| Urticaria — Mild | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urticaria — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urticaria — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urticaria — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Max. Systemic Symptoms — None | 8 | 5 | 4 | 10 | 11 | 8 | 1 |
| Max. Systemic Symptoms — Mild | 7 | 9 | 8 | 5 | 8 | 10 | 2 |
| Max. Systemic Symptoms — Moderate | 4 | 5 | 7 | 6 | 1 | 3 | 0 |
| Max. Systemic Symptoms — Severe | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Max. Systemic Symptoms — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Temperature — None | 17 | 18 | 18 | 21 | 20 | 20 | 3 |
| Temperature — Mild | 2 | 1 | 3 | 0 | 0 | 0 | 0 |
| Temperature — Moderate | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Temperature — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Temperature — Potentially Life-threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
| U/L | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| ALT (SGPT) (U/L)- Screening | 16 (11 to 21) | 16 (13 to 21) | 16 (12 to 21) | 14 (12 to 17) | 18 (10.5 to 20) | 13 (13 to 20) | 13 (12 to 16) |
| ALT (SGPT) (U/L)- 0/Enrollment | 14 (9 to 17) | 16 (12 to 17) | 19 (12 to 22) | 13.5 (10 to 21) | 13 (11.5 to 21.5) | 12 (10 to 20) | 17 (15 to 33) |
| ALT (SGPT) (U/L)- 56 | 15 (10 to 23) | 16 (12 to 21) | 15 (12.5 to 23) | 13 (10 to 21) | 15 (11 to 24) | 13 (11 to 23) | 31 (13 to 114) |
| ALT (SGPT) (U/L)- 112 | 16 (11 to 18) | 20 (13 to 23) | 13 (11.5 to 20.5) | 12 (12 to 18) | 16 (14 to 25) | 14 (10.5 to 20.5) | 19 (16 to 42) |
| ALT (SGPT) (U/L)- 168 | 13.5 (11 to 21) | 14.5 (13 to 23) | 15 (10 to 21) | 14 (10 to 24.5) | 16.5 (14 to 28) | 15 (12 to 23) | 19 (13 to 38) |
| ALT (SGPT) (U/L)- 224 | 18 (10.5 to 22.5) | 17 (13 to 21) | 15.5 (11.5 to 19.5) | 13 (11 to 25) | 14 (12 to 20) | 14.5 (12.5 to 19) | 17 (13 to 39) |
| ALT (SGPT) (U/L)- 280 | 16 (10 to 29) | 18 (14 to 25) | 15 (13 to 20) | 15 (11 to 23) | 17 (11 to 22) | 14 (11 to 23) | 18 (14 to 22) |
| ALT (SGPT) (U/L)- 336 | 15 (11 to 23) | 17 (15 to 18) | 14.5 (11 to 22) | 15 (11 to 20) | 16 (11.5 to 20) | 15 (13 to 18) | 13 (11 to 41) |
| ALT (SGPT) (U/L)- 392 | 17 (10 to 34) | 16 (12 to 21) | 19 (11 to 23) | 15 (10 to 24) | 16 (14 to 28) | 15 (12 to 17) | 18 (14 to 39) |
| ALT (SGPT) (U/L)- 448 | 13 (11 to 20) | 16.5 (13.5 to 20.5) | 17.5 (13 to 19.5) | 16 (10 to 22) | 18 (11 to 32) | 13 (11 to 18) | 16 (14 to 38) |
| ALT (SGPT) (U/L)- 504 | 12 (9 to 16) | 15 (12.5 to 31) | 13.5 (11 to 16.5) | 14.5 (10 to 22) | 16.5 (10 to 20.5) | 17 (12 to 21) | 15 (11 to 53) |
| ALT (SGPT) (U/L)- 728 | 19 (19 to 19) | 16 (15 to 26) | 16 (13 to 28.5) | 18.5 (15 to 20) | 18 (12.5 to 25) | 14 (9 to 26) | 26 (26 to 26) |
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
| mg/dL | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| Creatinine (mg/dL)- Screening | 0.85 (0.69 to 1) | 0.92 (0.78 to 1) | 0.84 (0.76 to 0.96) | 0.79 (0.7 to 0.9) | 0.84 (0.77 to 0.91) | 0.86 (0.72 to 0.98) | 0.74 (0.66 to 0.78) |
| Creatinine (mg/dL)- 0/Enrollment | 0.8 (0.76 to 1.05) | 0.93 (0.81 to 1) | 0.83 (0.72 to 0.93) | 0.83 (0.78 to 1.02) | 0.8 (0.65 to 0.9) | 0.83 (0.71 to 0.93) | 0.77 (0.64 to 0.81) |
| Creatinine (mg/dL)- 56 | 0.84 (0.7 to 1) | 0.9 (0.8 to 0.98) | 0.94 (0.75 to 1.02) | 0.82 (0.74 to 0.91) | 0.82 (0.68 to 1) | 0.8 (0.74 to 0.97) | 0.7 (0.66 to 0.74) |
| Creatinine (mg/dL)- 112 | 0.8 (0.69 to 0.89) | 0.88 (0.79 to 0.94) | 0.88 (0.71 to 1.02) | 0.86 (0.76 to 0.93) | 0.79 (0.7 to 0.96) | 0.84 (0.74 to 0.96) | 0.72 (0.64 to 0.75) |
| Creatinine (mg/dL)- 168 | 0.86 (0.75 to 0.92) | 0.91 (0.8 to 1) | 0.81 (0.73 to 0.93) | 0.83 (0.77 to 1) | 0.81 (0.7 to 0.95) | 0.9 (0.75 to 1) | 0.7 (0.68 to 0.79) |
| Creatinine (mg/dL)- 224 | 0.79 (0.69 to 0.9) | 0.86 (0.72 to 0.99) | 0.81 (0.72 to 0.95) | 0.81 (0.77 to 0.89) | 0.83 (0.67 to 0.94) | 0.82 (0.73 to 0.97) | 0.72 (0.68 to 0.8) |
| Creatinine (mg/dL)- 280 | 0.81 (0.71 to 0.88) | 0.89 (0.77 to 1.07) | 0.78 (0.72 to 0.95) | 0.81 (0.76 to 0.95) | 0.85 (0.7 to 0.9) | 0.89 (0.73 to 0.96) | 0.72 (0.7 to 0.74) |
| Creatinine (mg/dL)- 336 | 0.84 (0.69 to 0.9) | 0.85 (0.76 to 0.99) | 0.85 (0.72 to 0.93) | 0.84 (0.77 to 0.95) | 0.87 (0.77 to 1.01) | 0.87 (0.77 to 0.99) | 0.78 (0.7 to 0.89) |
| Creatinine (mg/dL)- 392 | 0.88 (0.7 to 0.9) | 0.95 (0.8 to 1.02) | 0.82 (0.8 to 0.96) | 0.85 (0.72 to 0.96) | 0.89 (0.76 to 1) | 0.89 (0.8 to 1) | 0.75 (0.71 to 0.9) |
| Creatinine (mg/dL)- 448 | 0.82 (0.76 to 0.91) | 0.9 (0.81 to 1) | 0.8 (0.72 to 0.91) | 0.81 (0.74 to 0.96) | 0.9 (0.74 to 0.97) | 0.84 (0.75 to 0.97) | 0.75 (0.7 to 0.76) |
| Creatinine (mg/dL)- 504 | 0.87 (0.76 to 1.06) | 0.92 (0.78 to 1.08) | 0.78 (0.71 to 0.98) | 0.85 (0.78 to 0.95) | 0.8 (0.72 to 0.86) | 0.88 (0.7 to 0.99) | 0.81 (0.7 to 0.84) |
| Creatinine (mg/dL)- 728 | 1.1 (1.1 to 1.1) | 1.1 (0.96 to 1.15) | 0.77 (0.68 to 0.92) | 0.87 (0.8 to 1.14) | 0.81 (0.77 to 0.86) | 0.89 (0.78 to 0.92) | 0.66 (0.66 to 0.66) |
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
| g/dL | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| Hemoglobin (g/dL)- Screening | 13.3 (12.7 to 14) | 14.2 (13.5 to 15.3) | 13.8 (13.3 to 14.8) | 13.1 (12.7 to 14.1) | 13.8 (13.15 to 15.1) | 14.4 (13 to 15.2) | 13.4 (12.1 to 14.1) |
| Hemoglobin (g/dL)- 0/Enrollment | 13.1 (12.3 to 14.2) | 13.9 (12.6 to 14.7) | 13.8 (12.8 to 14.5) | 13 (12.25 to 13.7) | 13.55 (13 to 15.2) | 14.1 (12.6 to 15) | 12.5 (11.7 to 13.4) |
| Hemoglobin (g/dL)- 56 | 13.35 (12.7 to 13.8) | 14.25 (13.6 to 15.1) | 13.4 (12.45 to 14.85) | 12.9 (12.5 to 13.9) | 13.8 (12.8 to 14.6) | 14.4 (12 to 14.9) | 12.6 (12 to 13.1) |
| Hemoglobin (g/dL)- 112 | 12.7 (11.9 to 13.9) | 13.95 (13.1 to 14.7) | 13.6 (12.55 to 15.15) | 13.1 (12.4 to 13.7) | 13.7 (12.6 to 14.6) | 14.45 (13.1 to 15.2) | 12.6 (12.2 to 14.1) |
| Hemoglobin (g/dL)- 168 | 13.7 (12.65 to 14.75) | 14.1 (13 to 14.8) | 13.65 (13.1 to 15.5) | 13.25 (12.05 to 13.85) | 13.5 (13 to 14.7) | 14.5 (12.4 to 15.1) | 12.8 (12.3 to 13.8) |
| Hemoglobin (g/dL)- 224 | 12.95 (12.3 to 13.8) | 13.7 (12.9 to 14.8) | 13.2 (12.5 to 14.95) | 13.5 (11.9 to 14.2) | 13.6 (13.3 to 14.7) | 14.15 (12.3 to 15) | 13.1 (11.8 to 13.3) |
| Hemoglobin (g/dL)- 280 | 13.3 (12.6 to 14) | 13.7 (13.1 to 14.4) | 13.1 (12.9 to 14.7) | 13.3 (12.1 to 14.3) | 13.6 (12.9 to 14.6) | 14.2 (11.8 to 14.9) | 13.3 (12.2 to 14.4) |
| Hemoglobin (g/dL)- 336 | 13.3 (12.5 to 14.4) | 13.6 (12.4 to 14.8) | 13.3 (12.3 to 15) | 13.3 (12.5 to 14.2) | 13.5 (12.75 to 15.2) | 14.2 (13.4 to 15.1) | 12.9 (12.2 to 13.5) |
| Hemoglobin (g/dL)- 392 | 13.3 (12.4 to 14.2) | 14.2 (13.2 to 14.8) | 13.5 (12.6 to 15.3) | 13.4 (12.5 to 14.3) | 13.5 (13 to 14.7) | 14.3 (12.6 to 14.9) | 12.6 (12.6 to 14.9) |
| Hemoglobin (g/dL)- 448 | 12.9 (12.5 to 13.5) | 13.95 (12.85 to 14.55) | 13.3 (12.2 to 14.4) | 13.3 (12.3 to 13.9) | 13.6 (12.7 to 14.8) | 14.2 (12.3 to 14.9) | 13 (11.9 to 13.7) |
| Hemoglobin (g/dL)- 504 | 13.25 (12.3 to 14.05) | 14.35 (13.2 to 14.8) | 13.4 (12.6 to 13.9) | 13 (12.4 to 14.6) | 13.9 (12.85 to 14.75) | 14.4 (13.2 to 15.6) | 12.9 (12.1 to 14) |
| Hemoglobin (g/dL)- 728 | 12.7 (12.7 to 12.7) | 14.7 (13.4 to 15) | 13.1 (12.45 to 14.55) | 14.9 (12.8 to 15.4) | 14.6 (13.65 to 15.5) | 14 (12.65 to 15.05) | 12.5 (12.5 to 12.5) |
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
| 1000 cells /cubic mm | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| Neutrophils (1000/cubic mm)- Screening | 3.84 (2.6 to 5) | 3.7 (2.95 to 4.15) | 3.72 (2.8 to 4.19) | 3.24 (2.7 to 3.93) | 3.76 (2.77 to 5.19) | 2.82 (2.3 to 4.51) | 3.37 (3.3 to 7.32) |
| Neutrophils (1000/cubic mm)- 0/Enrollment | 2.95 (2.49 to 4.67) | 4.01 (3.16 to 4.73) | 3.92 (2.62 to 4.95) | 2.98 (2.3 to 3.97) | 3.31 (2.92 to 4.17) | 3.16 (2.42 to 3.94) | 5.82 (2.98 to 6.61) |
| Neutrophils (1000/cubic mm)- 56 | 3.12 (2.18 to 3.8) | 3.83 (3.02 to 4.94) | 4 (2.84 to 4.61) | 2.78 (2.4 to 4.06) | 3.47 (2.74 to 4.2) | 3.28 (2.27 to 4.07) | 7.27 (6.07 to 7.95) |
| Neutrophils (1000/cubic mm)- 112 | 3.65 (3 to 4.07) | 3.87 (3.25 to 4.61) | 3.89 (2.8 to 5.28) | 3.03 (2.4 to 3.35) | 3.02 (2.62 to 3.61) | 3.17 (2.5 to 4.1) | 5.9 (4.9 to 6.6) |
| Neutrophils (1000/cubic mm)- 168 | 3.35 (2.07 to 4.77) | 3.1 (2.66 to 3.87) | 3.61 (2.65 to 4.35) | 3.17 (2.68 to 4.42) | 3.19 (2.75 to 4.06) | 2.84 (2.4 to 4.2) | 6.19 (4.85 to 7.03) |
| Neutrophils (1000/cubic mm)- 224 | 2.94 (1.95 to 3.82) | 3.55 (2.66 to 3.9) | 3.53 (2.73 to 4.29) | 2.89 (2.33 to 3.66) | 3.02 (2.44 to 3.7) | 2.75 (2.31 to 3.53) | 4.96 (4.85 to 6.87) |
| Neutrophils (1000/cubic mm)- 280 | 2.69 (2.02 to 3.9) | 3.64 (2.7 to 4.72) | 3.57 (2.98 to 4.6) | 3.12 (2.5 to 4.06) | 3.15 (2.53 to 4.83) | 2.94 (2.21 to 3.72) | 5.27 (4.54 to 5.99) |
| Neutrophils (1000/cubic mm)- 336 | 3.06 (2.2 to 4.69) | 3.55 (2.5 to 3.99) | 4.17 (3.14 to 4.52) | 3.04 (2.3 to 3.59) | 3.08 (2.33 to 3.66) | 2.83 (2.46 to 3.47) | 6.51 (5 to 7.58) |
| Neutrophils (1000/cubic mm)- 392 | 3.13 (2.34 to 4.34) | 3.61 (2.86 to 4.26) | 3.69 (2.85 to 4.27) | 2.86 (2.51 to 3.5) | 3.53 (2.7 to 3.94) | 2.84 (2.42 to 3.75) | 6.13 (5.04 to 7.56) |
| Neutrophils (1000/cubic mm)- 448 | 3.11 (2.34 to 4.16) | 3.76 (2.75 to 4.9) | 3.74 (3.14 to 5.09) | 3.05 (2.5 to 3.89) | 2.97 (2.18 to 4.47) | 3.04 (2.24 to 4.24) | 6.24 (5.09 to 6.46) |
| Neutrophils (1000/cubic mm)- 504 | 3.38 (1.97 to 3.66) | 3.86 (2.8 to 4.59) | 3.91 (2.53 to 5.81) | 2.81 (2.39 to 3.44) | 3.39 (2.72 to 3.71) | 3.02 (2.1 to 3.65) | 6.42 (4.95 to 8.12) |
| Neutrophils (1000/cubic mm)- 728 | 4.56 (4.56 to 4.56) | 4.25 (2.7 to 4.95) | 4.02 (3.25 to 5.21) | 2.3 (2.2 to 2.6) | 2.93 (2.45 to 3.78) | 3.63 (3.13 to 4.64) | 4.8 (4.8 to 4.8) |
| Lymphocytes (1000/cubic mm)- Screening | 2 (1.64 to 2.4) | 1.98 (1.7 to 2.44) | 2.04 (1.48 to 2.14) | 1.6 (1.4 to 2.07) | 1.92 (1.71 to 2.26) | 1.86 (1.66 to 2.67) | 3.06 (2.14 to 3.25) |
| Lymphocytes (1000/cubic mm)- 0/Enrollment | 1.86 (1.72 to 2.1) | 1.85 (1.6 to 2.25) | 1.87 (1.56 to 2.04) | 1.64 (1.44 to 2.21) | 1.86 (1.63 to 2.23) | 1.95 (1.55 to 2.29) | 2.94 (2.22 to 3.22) |
| Lymphocytes (1000/cubic mm)- 56 | 1.98 (1.57 to 2.25) | 1.94 (1.56 to 2.11) | 1.99 (1.33 to 2.5) | 1.86 (1.55 to 2) | 2.12 (1.78 to 2.48) | 1.87 (1.68 to 2.44) | 2.97 (2.05 to 3.38) |
| Lymphocytes (1000/cubic mm)- 112 | 1.82 (1.59 to 2.07) | 1.8 (1.5 to 2.24) | 2.04 (1.55 to 2.46) | 1.77 (1.4 to 2.03) | 1.91 (1.76 to 2.16) | 1.93 (1.51 to 2.36) | 3.46 (2.34 to 3.55) |
| Lymphocytes (1000/cubic mm)- 168 | 1.76 (1.53 to 1.99) | 1.8 (1.53 to 1.96) | 1.86 (1.53 to 2.07) | 1.61 (1.31 to 1.97) | 1.97 (1.65 to 2.26) | 1.89 (1.4 to 2.33) | 3.27 (2.17 to 3.33) |
| Lymphocytes (1000/cubic mm)- 224 | 1.65 (1.44 to 2.12) | 1.91 (1.6 to 2.1) | 2.01 (1.68 to 2.51) | 1.61 (1.41 to 1.99) | 1.94 (1.68 to 2.23) | 1.74 (1.49 to 2.37) | 3.13 (1.91 to 3.85) |
| Lymphocytes (1000/cubic mm)- 280 | 1.93 (1.75 to 2.13) | 1.71 (1.59 to 2.1) | 1.73 (1.3 to 2.32) | 1.7 (1.4 to 1.9) | 2.1 (1.81 to 2.66) | 1.92 (1.78 to 2.54) | 2.86 (2.15 to 3.58) |
| Lymphocytes (1000/cubic mm)- 336 | 2 (1.62 to 2.06) | 1.69 (1.5 to 2.05) | 2.16 (1.63 to 3.01) | 1.76 (1.21 to 2.18) | 2.12 (1.81 to 2.41) | 1.82 (1.54 to 2.21) | 2.95 (1.79 to 3.82) |
| Lymphocytes (1000/cubic mm)- 392 | 1.79 (1.53 to 2.08) | 1.8 (1.51 to 2.1) | 2.01 (1.43 to 2.85) | 1.58 (1.38 to 1.93) | 1.91 (1.7 to 2.3) | 1.82 (1.39 to 2.3) | 2.82 (1.46 to 3.1) |
| Lymphocytes (1000/cubic mm)- 448 | 1.89 (1.68 to 2) | 1.83 (1.52 to 2.11) | 1.96 (1.34 to 2.44) | 1.8 (1.4 to 1.96) | 1.89 (1.63 to 2.39) | 1.99 (1.44 to 2.31) | 2.87 (1.94 to 3.52) |
| Lymphocytes (1000/cubic mm)- 504 | 1.92 (1.54 to 2.28) | 1.89 (1.65 to 2.12) | 1.84 (1.5 to 2.26) | 1.79 (1.42 to 2.09) | 1.94 (1.85 to 2.29) | 1.76 (1.4 to 2.3) | 2.96 (1.3 to 3.02) |
| Lymphocytes (1000/cubic mm)- 728 | 1.85 (1.85 to 1.85) | 1.7 (1.5 to 1.95) | 2.24 (1.79 to 3) | 1.5 (1.4 to 1.51) | 2.65 (1.95 to 3.45) | 1.69 (1.52 to 2.03) | 3.89 (3.89 to 3.89) |
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
| 1000 cells/cubic mm | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| WBC (1000/cubic mm)- Screening | 6.4 (5 to 7.8) | 6.15 (5.36 to 7.44) | 6.8 (5.1 to 7.6) | 6.06 (4.54 to 6.59) | 6.7 (5.08 to 7.6) | 5.9 (4.71 to 8.5) | 7.1 (5.9 to 11.4) |
| WBC (1000/cubic mm)- 0/Enrollment | 6.2 (4.7 to 7.37) | 6.9 (5.4 to 7.7) | 6.51 (4.9 to 7.5) | 5.65 (4.56 to 6.43) | 6.1 (5.56 to 6.85) | 5.9 (4.73 to 6.79) | 9.8 (5.7 to 10.2) |
| WBC (1000/cubic mm)- 56 | 5.41 (4.6 to 7.1) | 6.76 (5.5 to 7.69) | 6.45 (5.34 to 8.39) | 5.44 (4.98 to 6.44) | 6.1 (5.6 to 7.5) | 5.9 (4.72 to 6.9) | 10.1 (9.9 to 11.8) |
| WBC (1000/cubic mm)- 112 | 6.23 (5.1 to 6.7) | 6.39 (5.71 to 7.7) | 6.67 (5.44 to 7.98) | 5.4 (4.34 to 6.21) | 5.85 (5.09 to 6.7) | 6 (5.05 to 7.78) | 9.7 (8.9 to 10.1) |
| WBC (1000/cubic mm)- 168 | 5.81 (4.61 to 7.1) | 5.51 (5.2 to 5.96) | 6.03 (5.25 to 7.6) | 5.28 (4.6 to 7.33) | 5.87 (4.71 to 7.01) | 5.7 (4.7 to 7.47) | 8.9 (8.7 to 10.9) |
| WBC (1000/cubic mm)- 224 | 6.5 (4.47 to 6.8) | 5.93 (5.17 to 6.7) | 6.35 (4.88 to 7.52) | 5.3 (4.32 to 6) | 6 (5.2 to 6.6) | 5.4 (4.42 to 7.62) | 8.8 (7.2 to 11.3) |
| WBC (1000/cubic mm)- 280 | 6.26 (5.3 to 7.18) | 6.59 (5.6 to 7.21) | 7 (5.13 to 7.5) | 5.56 (4.9 to 6.3) | 6.4 (5 to 7.3) | 5.8 (4.55 to 6.83) | 8.7 (7.2 to 10.2) |
| WBC (1000/cubic mm)- 336 | 5.39 (4.3 to 7.57) | 6 (4.95 to 6.84) | 7.04 (5.74 to 8.4) | 5.43 (4.3 to 6.1) | 5.76 (5.37 to 6.39) | 5.49 (4.7 to 6.13) | 8.8 (8.6 to 12.1) |
| WBC (1000/cubic mm)- 392 | 5.43 (4.4 to 6.9) | 5.9 (5.53 to 7.03) | 6.6 (5.29 to 7.31) | 5.08 (4.4 to 5.93) | 6.13 (5.2 to 7.5) | 5.6 (4.9 to 6.35) | 9.5 (8.5 to 9.9) |
| WBC (1000/cubic mm)- 448 | 5.66 (4.6 to 6.6) | 6.26 (5.35 to 7.3) | 6 (5.23 to 8.22) | 5.45 (4.66 to 6.71) | 6.7 (4.45 to 7.1) | 5.7 (4.46 to 7) | 8.6 (8.5 to 10.6) |
| WBC (1000/cubic mm)- 504 | 5.67 (4.51 to 6.65) | 6.3 (5.32 to 7.28) | 6.32 (5.2 to 8.91) | 5.55 (4.4 to 6.16) | 6.16 (5.51 to 6.7) | 5.05 (4 to 6.2) | 8.7 (8.2 to 11.9) |
| WBC (1000/cubic mm)- 728 | 7.12 (7.12 to 7.12) | 6.6 (5 to 7.39) | 7.02 (5.52 to 56.95) | 4.8 (3.86 to 6) | 6.6 (6.15 to 7) | 6.18 (5.8 to 7.08) | 9.3 (9.3 to 9.3) |
| Platelets (1000/cubic mm)- Screening | 260 (234.9 to 295.1) | 251 (233.6 to 265) | 271 (228 to 328.3) | 273 (209.8 to 332) | 244.5 (214.5 to 289.5) | 240.1 (223.1 to 276) | 315 (246 to 334) |
| Platelets (1000/cubic mm)- 0/Enrollment | 254.9 (229.1 to 291.1) | 239 (224 to 274) | 254 (219 to 317) | 270 (207.95 to 313.5) | 247 (210.5 to 281.75) | 244.5 (221 to 275) | 283 (249 to 294) |
| Platelets (1000/cubic mm)- 56 | 262.65 (235 to 278.7) | 255 (244 to 273) | 275.5 (238.5 to 346.1) | 283 (201 to 309) | 246 (218 to 293) | 246 (217 to 272.4) | 326 (284 to 337) |
| Platelets (1000/cubic mm)- 112 | 244.45 (221 to 276) | 250 (231 to 268) | 284.5 (252.5 to 337.65) | 267 (196 to 303) | 252.8 (204 to 283) | 261.5 (209.55 to 286.8) | 316 (279 to 338) |
| Platelets (1000/cubic mm)- 168 | 255.5 (234.65 to 269.05) | 255.5 (229 to 282) | 278.5 (242 to 311) | 271 (202.2 to 319.5) | 240.5 (203 to 299) | 257 (205.7 to 280) | 303 (302 to 328) |
| Platelets (1000/cubic mm)- 224 | 264 (227.5 to 277.95) | 252 (228 to 277) | 283 (250.5 to 348.5) | 252 (198 to 324) | 234 (195 to 303) | 256.5 (205.15 to 281.1) | 341 (288 to 350) |
| Platelets (1000/cubic mm)- 280 | 252.9 (229.6 to 303) | 249 (221 to 278) | 278 (222 to 338) | 250 (195 to 333) | 254.45 (215 to 287) | 257 (209 to 303.3) | 284.5 (243 to 326) |
| Platelets (1000/cubic mm)- 336 | 242 (210 to 275) | 246 (217 to 277) | 270.5 (246 to 314) | 256 (193 to 348) | 238.5 (200 to 293.15) | 233 (206.3 to 259) | 310 (286 to 324) |
| Platelets (1000/cubic mm)- 392 | 255.85 (234.6 to 282) | 255.5 (237 to 283) | 265 (244 to 311) | 251 (181 to 332) | 252 (213 to 294) | 250 (210.5 to 279.1) | 319 (283 to 321) |
| Platelets (1000/cubic mm)- 448 | 249 (241 to 276.8) | 243.5 (233 to 272.5) | 264 (223.5 to 306) | 260 (212 to 300) | 254.4 (188 to 308) | 255 (214.7 to 296) | 336 (293 to 346) |
| Platelets (1000/cubic mm)- 504 | 271.35 (244.5 to 289.6) | 252.65 (234.75 to 285) | 257.5 (246 to 338) | 268.5 (210.05 to 296) | 248.5 (193.5 to 280.5) | 251 (208.2 to 284) | 323 (251 to 325) |
| Platelets (1000/cubic mm)- 728 | 283.2 (283.2 to 283.2) | 278 (210.4 to 297) | 250 (208 to 283) | 233 (191 to 249) | 263.5 (243.95 to 295.5) | 302 (273.5 to 382.5) | 327 (327 to 327) |
The number (percentage) of participants with lab grade \>= 1 for alanine aminotransferase (ALT), creatinine, hemoglobin, lymphocyte count, neutrophil count, platelets, white blood cells (WBC) was summarized by arm
| Participants | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| WBC (1000/cubic mm)- Screening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 0/Enrollment | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 112 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 168 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 224 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 280 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 336 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 392 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 448 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 504 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC (1000/cubic mm)- 728 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- Screening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 0/Enrollment | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 112 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 168 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 224 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 280 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 336 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 392 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 448 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 504 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (1000/cubic mm)- 728 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- Screening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 0/Enrollment | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 112 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 168 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 224 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 280 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 336 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 392 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 448 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 504 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (g/dL)- 728 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- Screening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 0/Enrollment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 112 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 168 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 224 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 280 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 336 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 392 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 448 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 504 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes (1000/cubic mm)- 728 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- Screening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 0/Enrollment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 112 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 168 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 224 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 280 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 336 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 392 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 448 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 504 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (1000/cubic mm)- 728 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT (SGPT) (U/L)- Screening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT (SGPT) (U/L)- 0/Enrollment | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| ALT (SGPT) (U/L)- 56 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| ALT (SGPT) (U/L)- 112 | 0 | 0 | 1 | 0 | 2 | 1 | 1 |
| ALT (SGPT) (U/L)- 168 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| ALT (SGPT) (U/L)- 224 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| ALT (SGPT) (U/L)- 280 | 1 | 0 | 0 | 2 | 1 | 1 | 0 |
| ALT (SGPT) (U/L)- 336 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| ALT (SGPT) (U/L)- 392 | 3 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT (SGPT) (U/L)- 448 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| ALT (SGPT) (U/L)- 504 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| ALT (SGPT) (U/L)- 728 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine (mg/dL)- Screening | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine (mg/dL)- 0/Enrollment | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Creatinine (mg/dL)- 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine (mg/dL)- 112 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Creatinine (mg/dL)- 168 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Creatinine (mg/dL)- 224 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Creatinine (mg/dL)- 280 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Creatinine (mg/dL)- 336 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Creatinine (mg/dL)- 392 | 0 | 0 | 0 | 2 | 3 | 0 | 0 |
| Creatinine (mg/dL)- 448 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Creatinine (mg/dL)- 504 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Creatinine (mg/dL)- 728 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VRC07523LS serum concentrations measured in healthy human subjects after up to five administrations of the study product via the IV, SC or IM routes at various doses. Serum concentrations between the first and second study product administrations (Target Visit Day 0-112) were measured using ELISA assay in all enrolled participants. Serum concentrations after the second study product administrations (Target Visit Day 168-784) were measured using BAMA (LUMINEX) assay in a subset of participants enrolled in each treatment group and all particiants in plocebo group. serum concentrations below the lower limit of quantification (LLoQ) were replaced by half the LLoQ. Thus, concentrations below the LLoQ when measured by the ELISA assay were replaced by 0.5 ug/ml and concentrations below the LLoQ when measured by the BAMA assay were replaced by 0.02285 ug/ml.
| ug/ml | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| IDVRC07-523LS (Day-000) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) |
| IDVRC07-523LS (Day-003) | 43.13 (38.57 to 52.81) | 80.7 (73.52 to 101.15) | 332.57 (260 to 455.77) | 11.06 (7.95 to 15.28) | 17.81 (14.57 to 26.49) | 16.71 (15.16 to 19.14) | 0.5 (0.5 to 0.5) |
| IDVRC07-523LS (Day-006) | 27.71 (23.7 to 33.64) | 59.05 (49.91 to 71.34) | 224 (200.96 to 261.88) | 11.04 (8.26 to 13.21) | 22.22 (18.81 to 26.26) | 16.03 (13.89 to 17.81) | 0.5 (0.5 to 0.5) |
| IDVRC07-523LS (Day-028) | 14.56 (13.48 to 17.86) | 27.86 (25.92 to 36.53) | 125.17 (110.6 to 132.2) | 6.79 (5.63 to 8.36) | 13.37 (11.89 to 17.65) | 10.03 (8.91 to 11.87) | 0.5 (0.5 to 0.5) |
| IDVRC07-523LS (Day-056) | 10.67 (8.26 to 12.76) | 17.08 (15.32 to 21.55) | 68.97 (59.45 to 75.21) | 5.02 (3.81 to 5.7) | 7.63 (6.57 to 10.43) | 6.27 (5.72 to 7.39) | 0.5 (0.5 to 0.5) |
| IDVRC07-523LS (Day-084) | 5.43 (4.69 to 6.9) | 12.19 (10.33 to 14.17) | 45.27 (36.41 to 52.23) | 2.99 (0.86 to 4.12) | 5.9 (4.89 to 7.23) | 4.29 (3.48 to 5.33) | 0.5 (0.5 to 0.5) |
| IDVRC07-523LS (Day-112) | 4.08 (3.09 to 4.84) | 6.51 (5.33 to 7.59) | 26.83 (22.83 to 30.69) | 0.5 (0.5 to 2.14) | 3.95 (2.72 to 4.58) | 2.98 (1.88 to 3.53) | 0.5 (0.5 to 0.5) |
| IDVRC07-523LS (Day-168) | 13.14 (8.75 to 14.82) | 22.46 (19.66 to 24.95) | 98.34 (93.59 to 111.17) | 5.77 (4.19 to 6.56) | 10.99 (10.15 to 12.2) | 8.09 (6.07 to 8.74) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-224) | 5.55 (5.12 to 7.08) | 9.83 (8.89 to 11.74) | 36.11 (29.29 to 49.15) | 2.31 (1.11 to 3.17) | 5.95 (4.95 to 7.17) | 3.53 (2.41 to 4.52) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-280) | 12.17 (11.3 to 14.1) | 25.77 (20.13 to 27.8) | 93.35 (81.62 to 100.24) | 7.52 (3.42 to 8.66) | 13.65 (10.92 to 17.55) | 7.79 (5.88 to 10.33) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-336) | 5.5 (3.8 to 6.52) | 11.15 (7.74 to 12.77) | 38.01 (25.6 to 48.67) | 2.16 (1.49 to 3.2) | 6.39 (4.86 to 8.61) | 3.62 (2.82 to 4.01) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-392) | 13.31 (10.04 to 14.6) | 25.88 (22.09 to 30.52) | 98.93 (86.92 to 113.48) | 6.12 (3.94 to 8.47) | 12.76 (11.08 to 15.29) | 8.13 (6.66 to 9.47) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-448) | 5.6 (4.24 to 6.81) | 10.29 (9.04 to 15.12) | 40.22 (36.47 to 46.45) | 2.71 (2 to 4.39) | 6.06 (5.28 to 6.88) | 3.59 (3.23 to 4.26) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-504) | 14.18 (8.37 to 14.92) | 23.4 (20.28 to 28.7) | 98.2 (93.78 to 106.21) | 6.11 (4.77 to 8.11) | 13.22 (10.63 to 15.47) | 7.61 (6.58 to 8.92) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-560) | 5.08 (3.62 to 6.69) | 10.67 (9.21 to 15.27) | 41.17 (32.3 to 49.84) | 1.65 (1.42 to 3.68) | 7.17 (6.18 to 8.09) | 3.92 (3.56 to 4.32) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-616) | 2.7 (2.36 to 3.68) | 5.74 (4.59 to 6.72) | 20.78 (16.32 to 27.46) | 1.52 (0.58 to 1.96) | 3.63 (2.8 to 3.83) | 1.36 (0.89 to 1.69) | — |
| IDVRC07-523LS (Day-672) | 1.14 (0.95 to 1.18) | 2.81 (1.67 to 3.63) | 10.68 (9.02 to 11.7) | 0.78 (0.61 to 1.45) | 1.29 (0.91 to 1.52) | 1.25 (0.95 to 1.56) | — |
| IDVRC07-523LS (Day-728) | 0.47 (0.33 to 0.62) | 1.68 (0.59 to 2.27) | 5.87 (3.11 to 5.94) | 0.45 (0.45 to 0.85) | 0.74 (0.69 to 0.83) | 0.44 (0.33 to 0.47) | 0.02 (0.02 to 0.02) |
| IDVRC07-523LS (Day-784) | 0.51 (0.26 to 0.54) | 0.94 (0.72 to 1.09) | 2.17 (1.76 to 3.01) | 0.17 (0.1 to 0.33) | 0.36 (0.34 to 0.52) | 0.27 (0.2 to 0.29) | 0.02 (0.02 to 0.02) |
Antidrug antibodies (ADA) are most typically detected and characterized using a tiered testing strategy. In Tier I, a sensitive binding assay is used to determine if samples may have ADA present. In Tier II, the response is confirmed, typically by establishing the specificity of the response by competition with free drug. In Tier III, the response is characterized, typically with a neutralization reduction assay and/or a titering assay.
| Participants | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| 0 - Tier I | 2 | 2 | 0 | 2 | 0 | 1 | 0 |
| 0 - Tier II | 0 | 0 | — | 0 | — | 0 | — |
| 112 - Tier I | — | — | 0 | — | 0 | — | — |
| 224 - Tier I | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 224 - Tier II | — | — | — | 1 | — | — | — |
| 224 - Tier III | — | — | — | 0 | — | — | — |
| 448 - Tier I | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 448 - Tier II | — | 0 | — | — | — | — | — |
| 6 - Tier I | — | 0 | — | — | — | — | — |
Magnitude-breadth characterize the magnitude (ID50 or ID80 titers) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the fraction of assays with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) is calculated as the average of the log10-based ID50 or ID80 titers over the panel of isolates. Isolates includes: H703_0646_051sN, H703_1471_190s, H703_1750_140Es, H704_0726_080sN, H704_1535_030sN, H704_2544_140eN01, PVO.4.
| log10(titer) | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine |
|---|---|---|---|---|---|---|
| ID50 (Week-08) | 1.56 (1.44 to 1.56) | 1.89 (1.74 to 2) | 2.46 (2.38 to 2.54) | 1.34 (1.23 to 1.54) | 1.54 (1.4 to 1.55) | 1.39 (1.26 to 1.45) |
| ID50 (Week-72) | 1.62 (1.57 to 1.81) | 2.03 (1.79 to 2.12) | 2.6 (2.5 to 2.67) | 1.36 (1.25 to 1.55) | 1.6 (1.48 to 1.71) | 1.49 (1.42 to 1.57) |
| ID50 (Week-88) | 0.98 (0.96 to 1.11) | 1.4 (1.26 to 1.4) | 1.93 (1.85 to 2.07) | 0.8 (0.7 to 0.94) | 0.97 (0.89 to 0.98) | 0.9 (0.8 to 0.96) |
| ID80 (Week-08) | 1.14 (1.04 to 1.19) | 1.37 (1.33 to 1.42) | 1.97 (1.89 to 2.03) | 0.93 (0.89 to 1.11) | 1.15 (1.03 to 1.2) | 1.01 (0.91 to 1.08) |
| ID80 (Week-72) | 1.27 (1.16 to 1.33) | 1.49 (1.35 to 1.55) | 2.14 (2.02 to 2.16) | 1 (0.88 to 1.12) | 1.21 (1.12 to 1.29) | 1.13 (1.02 to 1.18) |
| ID80 (Week-88) | 0.85 (0.77 to 0.88) | 0.91 (0.88 to 0.95) | 1.45 (1.41 to 1.55) | 0.7 (0.7 to 0.74) | 0.84 (0.8 to 0.84) | 0.75 (0.72 to 0.79) |
Collected over The study Unsolicited AE reporting time frame is from study enrollment of a trial participant to (and including) the Week 112 visit (v20.0). The Solicited AE assessment were collected through 3 full days after each vaccination (vaccinations were given at weeks 0, 16, 32, 48 and 64).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Vaccine | 0/19 (0%) | 1/19 (5.3%) | 14/19 (73.7%) |
| Group 2: Vaccine | 0/19 (0%) | 1/19 (5.3%) | 16/19 (84.2%) |
| Group 3: Vaccine | 0/21 (0%) | 0/21 (0%) | 14/21 (66.7%) |
| Group 4: Vaccine | 0/21 (0%) | 1/21 (4.8%) | 18/21 (85.7%) |
| Group 5: Vaccine | 0/20 (0%) | 0/20 (0%) | 16/20 (80%) |
| Group 6: Vaccine | 0/21 (0%) | 0/21 (0%) | 17/21 (81%) |
| Group 7: Placebo | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| Any Event in SOCInfections and infestations | 0/19 | 1/19 | 0/21 | 0/21 | 0/20 | 0/21 | 0/3 |
| Staphylococcal infectionInfections and infestations | 0/19 | 1/19 | 0/21 | 0/21 | 0/20 | 0/21 | 0/3 |
| Any Event in SOCRenal and urinary disorders | 1/19 | 0/19 | 0/21 | 0/21 | 0/20 | 0/21 | 0/3 |
| Calculus urinaryRenal and urinary disorders | 1/19 | 0/19 | 0/21 | 0/21 | 0/20 | 0/21 | 0/3 |
| Any Event in SOCGeneral disorders | 0/19 | 0/19 | 0/21 | 1/21 | 0/20 | 0/21 | 0/3 |
| PyrexiaGeneral disorders | 0/19 | 0/19 | 0/21 | 1/21 | 0/20 | 0/21 | 0/3 |
| Event | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| Any Event in SOCInfections and infestations | 9/19 | 10/19 | 11/21 | 9/21 | 10/20 | 12/21 | 3/3 |
| Upper respiratory tract infectionInfections and infestations | 1/19 | 5/19 | 7/21 | 3/21 | 4/20 | 6/21 | 3/3 |
| Any Event in SOCInvestigations | 4/19 | 3/19 | 8/21 | 9/21 | 5/20 | 5/21 | 2/3 |
| Alanine aminotransferase increasedInvestigations | 3/19 | 1/19 | 3/21 | 3/21 | 2/20 | 2/21 | 2/3 |
| Any Event in SOCMusculoskeletal and connective tissue disorders | 1/19 | 4/19 | 1/21 | 6/21 | 4/20 | 2/21 | 2/3 |
| Any Event in SOCGastrointestinal disorders | 1/19 | 7/19 | 5/21 | 2/21 | 6/20 | 3/21 | 1/3 |
| Any Event in SOCEye disorders | 0/19 | 0/19 | 0/21 | 0/21 | 1/20 | 0/21 | 1/3 |
| Eczema eyelidsEye disorders | 0/19 | 0/19 | 0/21 | 0/21 | 0/20 | 0/21 | 1/3 |
| DiarrhoeaGastrointestinal disorders | 1/19 | 1/19 | 0/21 | 0/21 | 0/20 | 0/21 | 1/3 |
| Fungal infectionInfections and infestations | 0/19 | 0/19 | 0/21 | 0/21 | 0/20 | 0/21 | 1/3 |
| Age, Continuous(years) | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 30 (18 to 50) | 30 (18 to 48) | 23 (19 to 50) | 29 (20 to 49) | 27 (21 to 37) | 27 (19 to 43) | 31 (24 to 35) | 28 (18 to 50) |
| Age, Customized(Participants) | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Less than 18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 - 20 years | 4 | 3 | 4 | 1 | 0 | 2 | 0 | 14 |
| 21 - 30 years | 6 | 7 | 11 | 11 | 17 | 13 | 1 | 66 |
| 31 - 40 years | 6 | 7 | 4 | 3 | 3 | 3 | 2 | 28 |
| 41 - 50 years | 3 | 2 | 2 | 6 | 0 | 3 | 0 | 16 |
| Above 50 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 14 | 8 | 11 | 15 | 13 | 11 | 3 | 75 |
| Male | 5 | 11 | 10 | 6 | 7 | 10 | 0 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 5 | 2 | 0 | 2 | 0 | 12 |
| Not Hispanic or Latino | 19 | 16 | 16 | 19 | 20 | 19 | 3 | 112 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 3 | 0 | 1 | 1 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 4 | 2 | 5 | 6 | 6 | 0 | 28 |
| White | 12 | 10 | 13 | 10 | 11 | 12 | 3 | 71 |
| More than one race | 2 | 2 | 1 | 3 | 2 | 1 | 0 | 11 |
| Unknown or Not Reported | 0 | 2 | 2 | 3 | 0 | 1 | 0 | 8 |
| Region of Enrollment(Participants) | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| USA | 19 | 19 | 21 | 21 | 20 | 21 | 3 | 124 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Dec 2020, 33 months.
Results were first posted in Mar 2022, 1 year 3 months after primary completion.
Of 91 non-industry phase 1 interventional studies under HIV Infections, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 33 months is above that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VRC07-523LS
National Institute of Allergy and Infectious Diseases (NIAID) →